Cargando…

T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response

The role of T cell receptor (TCR) signaling for adaptive immune responses is essential. The ability to respond to a broad spectrum of tumor antigens requires an adaptive selection of various TCR. So far, little is known about the role of TCR richness and clonality in the cellular immune response to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kansy, Benjamin A., Shayan, Gulidanna, Jie, Hyun-Bae, Gibson, Sandra P., Lei, Yu L., Brandau, Sven, Lang, Stephan, Schmitt, Nicole C, Ding, Fei, Lin, Yan, Ferris, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205044/ https://www.ncbi.nlm.nih.gov/pubmed/30377562 http://dx.doi.org/10.1080/2162402X.2018.1494112

Ejemplares similares

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
por: Kansy, Benjamin A, et al.
Publicado: (2015)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer
por: Lu, Shanhong, et al.
Publicado: (2018)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)

The bidirectional tumor - mesenchymal stromal cell interaction promotes the progression of head and neck cancer
por: Kansy, Benjamin A, et al.
Publicado: (2014)

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
por: Pogorzelski, Michael, et al.
Publicado: (2021)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Immunological priming of mesenchymal stromal/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease via engagement of PD-1 ligands
por: Hackel, Alexander, et al.
Publicado: (2023)

Cervical lymph node diseases in children
por: Lang, Stephan, et al.
Publicado: (2014)

Immunotherapy – The New Era of Oncology
por: Kansy, Benjamin, et al.
Publicado: (2018)

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
por: Schuler, Patrick J, et al.
Publicado: (2011)

Lymph node ratio-based nomogram for prognosis evaluation and treatment optimization of non-metastatic oral cavity squamous cell carcinoma
por: Ma, Yuchao, et al.
Publicado: (2022)

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
por: Srivastava, Raghvendra M, et al.
Publicado: (2013)

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
por: Li, Jing, et al.
Publicado: (2015)

Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT
por: Theodoraki, Marie-Nicole, et al.
Publicado: (2019)

Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity
por: Gottschalk, Nina, et al.
Publicado: (2012)

Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines
por: Gottschalk, Nina, et al.
Publicado: (2012)

Bone marrow-derived mesenchymal stem cells migrate to healthy and damaged salivary glands following stem cell infusion
por: Schwarz, Silke, et al.
Publicado: (2014)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
por: Mallmann-Gottschalk, Nina, et al.
Publicado: (2019)

Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer: Correlation between ACAA2 and cetuximab resistance in CRC
por: Yuan, Yitao, et al.
Publicado: (2023)

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

AHNAK and Inflammatory Markers Predict Poor Survival in Laryngeal Carcinoma
por: Dumitru, Claudia A., et al.
Publicado: (2013)

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
por: Concha-Benavente, Fernando, et al.
Publicado: (2014)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2019)

Neutrophils Activate Tumoral CORTACTIN to Enhance Progression of Orohypopharynx Carcinoma
por: Dumitru, Claudia A., et al.
Publicado: (2013)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Evaluation of Immunoregulatory Biomarkers on Plasma Small Extracellular Vesicles for Disease Progression and Early Therapeutic Response in Head and Neck Cancer
por: Jablonska, Jadwiga, et al.
Publicado: (2022)

New therapeutic modalities in drug discovery and development: Insights & opportunities
por: Kansy, Manfred, et al.
Publicado: (2021)

Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations
por: Davis, Ruth J., et al.
Publicado: (2016)

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
por: Cheng, Yinwen, et al.
Publicado: (2021)

Comparison of Contrast-Enhanced Ultrasonography to Color Doppler Ultrasound in Evaluation of Carotid Body Tumors
por: Gu, Guangchao, et al.
Publicado: (2022)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance
por: Matić, Ivana Z., et al.
Publicado: (2018)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer
por: Pham, Quoc Thang, et al.
Publicado: (2021)

Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma
por: Höing, Benedikt, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ef00opcj24qvtdpbcrne25je71